There are few people as influential in the world of technology and data as Eric Lefkofsky. Eric Lefkofsky has largely worked out of Chicago with a special focus on data aggregation. Right now Eric Lefkofsky is focused on his newest project, Tempus. Tempus is a company that is looking to fundamentally change the way that cancer care facilities operate by focusing on data aggregation for both patients and genomicdata. Tempus is a unique idea that is also a natural progression from what the healthcare field has been doing for the past few years with EHRs. Let’s take a closer look at Lefkofsky’s work and goals with the company.
Eric Lefkofsky saw firsthand how cancer care facilities around the country can struggle to get data from one place to another. One of the large problems is that notes and details are notoriously hard to keep track of. From handwritten doctor’s notes to poorly organized EHRs, life saving information can have a hard time getting to where it needs to go. Lefkofsky uses this broad problem to point out how it can make specific, focused issues for cancer care patients: if one medication works for one patient, why won’t it work for another patient across the country?
In order to answer the question we highlighted above Eric Lefkofsky decided to focus his work on Tempus. Tempus was established in 2015 and since then it has reached a valuation of over $700 million in total. Tempus operates like a digital overlay that seeks to bring together patient and genomic data into one convenient location that can be accessed by patients and medical professionals. Tempus is an operating system that pools and aggregates data in a variety of different ways. Over the years costs of genome sequencing have come down and now Tempus is going to push the envelope even further in a life saving effort.
Tempus is attempting to make a broad and sweeping change to the cancer care world. So far Tempus has been partnered up with several professional facilities including Duke University School of Medicine, Mayo Clinic and the Cleveland Clinic as well.
Oncotarget is a free journal that was established in 2010. It is published by Impact Journals Its main focus is on matters dealing with health specifically on the care and treatment of cancer. The perspective of the patient is also included when it comes to these treatment methods. The chief editors of Oncotarget are Mikhal V. Blagosklonny and Andrei V. Gudkov. The journal looks into the impact of newly suggested protocols. Aspects such as the impact of the treatment on the quality of life and satisfaction one gets from the treatment are focused on. If the treatment proves to be beneficial more doctors will incorporate the procedure into their work.
Contents of the journal are posted on their Official Website on a weekly basis where any interested individual can see them. From this site individuals can get information on the different research that is being carried out to treat cancer. People can leave reviews on the site either giving positive or negative feedback. These will be used to make changes where necessary. Reviews also help determine the age groups visiting the site. This information will help the editors to write articles that will appeal to the specific age groups.Issues can be printed depending on what people demand. The aim of the Oncotarget team is to relay information regarding scientific results far and wide. This will help in maximizing the impact of scientific research that is being done.
The journal helps get rid of the border between different medical personnel who have various specialties. The fields of biomedical science are linked through this journal. This is because different professionals come to review the journal and give their insights on the topics.The continued success of the journal has prompted editors to focus on other areas apart from oncology. Areas such as pathology, immunology and autophagy are included in the articles. The popularity of Oncotarget is due to the team work of the professionals involved. Through this, insightful information is published. The impact factor that Oncotarget has is at 5.I68, which was recorded in 2016/2017. This number has gone up from 5.008 in 2015.
Eric Lefkofsky is considered to be one of America’s greatest entrepreneurs. The teacher, writer, philanthropist and business man created a variety of successful companies which we all know and love. Dedicated to giving, Eric leads many successful charities and organizations as well.
Eric grew up in a suburban community located in northern Michigan. Son of a school teacher and engineer, Eric Lefkofsky pursued law as an education. He graduated with honors from the well respected University of Michigan. After graduating, Lefkofsky then pursued a higher education in the same state. He completed his studies at The University of Michigan Law School. It was here he managed to secure his Juris Doctor.
The cofounder and CEO of Tempus, Eric and his company are working tirelessly to bettering lives of cancer patients. Tempus is commonly known for their cancer battling technologies. This innovative company allows doctors the opportunity most are denied. Physicians are given personalized cancer care treatment opportunity through analytical and machine learning platforms.
Tempus provides genomic sequencing service. They also provide molecular analyzing and therapeutic data allowing doctors to make the most accurate decisions. These decisions are based on real time data.
Eric Lefkofsky is also the cofounder of Lightbank. This financial organization specializes in investments. Lightbank offers various venture capitalist investment opportunities. The most known companies Lightbank invest in are Groupon, Mediaocean and InnerWorkings. Although the headquarters is located in Chicago, Loghtbank has made investments with companies across the nation.
Eric is also known for his professional teaching career. He has worked alongside many prestigious schools in the Midwest region. Eric teaches a wide range of courses providing insight on his professional and educational background.
Eric has taught Applied Technology at Kellstadt Graduate School of Business. He has also taught a course on Disruptive Business Models at Northwestern University. At Chicago Booth School of Business, Eric teaches a course on entrepreneurship and web based businesses. For more info about us: http://www.bizjournals.com/chicago/news/2016/10/20/groupon-founder-eric-lefkofsky-joins-steppenwolf.html click here.
The cofounder of Groupon is much more than a business man. With a passion for helping the community, Eric has since joined the Giving Pledge. The Giving Pledge is a campaign created by Bill Gates and Warren Buffett to encourage wealthy people to contribute their wealth to philanthropic causes.
Eric Lefkofsky also created a charitable trust. Content on helping others, Eric started the Lefkofsky foundation in 2006. The foundation supports science and children foundations. The Lefkofsky Foundation has collectively help fund over fifty total organizations.
Eric Lefkofsky Business
Many people today want to learn how to take their health to a new level. Millions of people every year struggle with diabetes and high blood pressure. For the vast majority of these people, a few lifestyle changes completely transform their health in less than a year. Now is a great time to learn about your health because there is so much information available.
There are a lot of companies that are taking healthcare industry by storm. These companies are transforming the way that people conduct their health, and they are ready for any challenge that comes their way. Eric Lefkofsky is one of the leaders in the business world who is tired of the typical healthcare system. He is working on a lot of projects in his business that will help other people throughout the world.
Many people like Eric Lefkofsky are frustrated with the healthcare system today. There is more technology than ever before, but the cost of health care continues to increase every year. Not only that, but he is tired of seeing people struggle with their health and wellness because they lack basic information.
Everyone knows that they should eat healthy and exercise. However, few people today are actually doing this. It is vital for people to start taking their heathy seriously. Eric Lefkofsky employees in his business are working on ways that they can teach people basic steps to get out of bad health. The company has already had success with many people who wanted transform their health.
When it comes to new technology in the world of healthcare, Eric Lefkofsky is one of the leaders in the field. However, it is also important to know that he truly cares about helping people. Although he runs a successful company, he is not just doing it for the money. He has a track record of success in helping his customers feel better and more energetic. In the world we live in today, the cost of healthcare continues to increase every year. Eric Lefkofsky is fighting to change that.
About Eric Lefkofsky: www.bizjournals.com/chicago/news/2017/04/12/groupon-co-founder-moves-to-help-youth-access-art.html
People excel by having access to secrets. These so-called secrets are not actually what they are called. It is the unrelenting adherence of individuals to them that make them one. Everybody may have access to them, but not everybody can hold-on to them in trying situations. Call them strategies, you will not be wrong. Clay B. Siegall has one strategy that has kept him going all these years. I got to know it when he was responding to questions in a recent interview. In his words, “Learn as much as you can; interact with very smart people who have expertise in many areas.” Narrowing this strategy to his profession, he put it this way: “An important component of our business strategy is collaborating with other industry leaders and innovators in oncology drug development.” He never sees himself or the company he runs as a island of knowledge, but can we find instances where he put this strategy into practice?
Clay B. Siegall holds a doctorate degree in Genetics from George Washington University. He is a Co-founder as well as the President, Chief Executive Officer and Board Chairman of Seattle Genetics since the inception of company in 1998. Being a specialist on targeted cancer therapies, Dr. Siegall entrenched into the fibers of the company a tradition of rigorous research, scientific innovation, drug development practices and unrelenting passion for assisting patients. Under his watch, the company has developed a number of effective antibody-drug conjugates (ADCs) with the FDA in 2011 approving the company’s first ADC product by the name ADCETRIS® (brentuximab vedotin). Thereafter, the company went into collaboration with Takeda Pharmaceutical Company making the drug a global brand available in over 65 countries.
Seattle Genetics has been involved in multiple strategic licenses for the purpose of financing its ADC technology. The company has had corporate agreements with companies such as Pfizer, GlaxoSmithKline, AbbVie and Genetics (Roche) generating well beyond $350 million. With the help of its numerous internal and collaborator programs, over 20 ADCs are in clinical development stages using Seattle Genetics’ technology.
Clay B. Siegall is one of the few indispensable hands combating the monster called cancer and providing hope of the eventual obliteration of the disease from planet earth.